We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Q BioMed Inc (CE) | USOTC:QBIO | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0005 | 0.00 | 01:00:00 |
Name of Selling Stockholder
|
Number of Shares of Common Stock Owned Prior to Offering(2)
|
Maximum Number of Shares of Common Stock to be Sold Pursuant to this Prospectus (3)
|
Number of Shares of Common Stock Owned After Offering (4)
|
Number of Shares of Common Stock
Which May Be Sold in this Offering as A Percentage of Currently Outstanding Shares (5)
|
Percentage of Shares of Common Stock Owned After the Offering (6)
|
YA II PN, LTD.(1)
|
594,000
|
1,313,797
|
324,000
|
11.4%
|
2.6%
|
(1)
|
YA II PN, Ltd (“YA”) is the investor under the Purchase Agreement. Yorkville Advisors Global, LP ("Yorkville LP") is YA II PN, Ltd.’s. investment manager and Yorkville Advisors Global II, LLC ("Yorkville LLC") is the General Partner of Yorkville LP. All investment decisions for YA II PN, Ltd. are made by Yorkville LLC's President and Managing Member, Mr. Mark Angelo. The address of YA is 1012 Springfield Avenue, Mountainside, NJ 07092, Attention: Mark Angelo, Portfolio Manager.
|
(2)
|
Includes 162,000 shares of common stock held by an affiliate under common control, 162,000 shares of common stock underlying warrants and 270,000 shares of common stock underlying the Convertible Notes (which are not exercisable if such conversion would result in beneficial ownership greater than 4.99% of all outstanding shares).
|
(3)
|
Includes shares of common stock underlying the Convertible Notes that may held by the selling stockholder that are covered by this prospectus, including any such securities that, due to contractual restrictions, may not be exercisable if such conversion would result in beneficial ownership greater than 4.99%.
|
(4)
|
Represents 162,000 shares of common stock held by an affiliate under common control, 162,000 shares of common stock underlying warrants and the difference between the maximum number of shares into which the principal and interest on the Convertible Notes may be converted and the shares being registered under the registration statement of which this prospectus forms a part.
|
(5)
|
Assumes that the total number of our issued and outstanding common shares remains unchanged at
11,496,169
prior to the issuance of the common shares underlying the Convertible Notes. If all of the shares are sold pursuant to this offering and the total number of our issued and outstanding common shares otherwise remains unchanged at
11,496,169
, such shares sold in this offering shall equal approximately 10.1% of the then issued outstanding shares of our common stock
|
(6)
|
Assumes that the total number of our issued and outstanding common shares remains unchanged at
11,496,169
prior to the issuance of the common shares underlying the Convertible Notes, that the selling stockholder exercises its right to convert all of the principal and interest on the convertible notes at the floor price of $2.00, that it sells all of the shares offered pursuant to this prospectus and that is sells no other shares of common stock beneficially owned by it.
|
1 Year Q BioMed (CE) Chart |
1 Month Q BioMed (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions